Abstract
Background/Objectives: Lower-grade glioma (LGG) is a type of brain tumor with a relatively better prognosis than glioblastoma. However, identifying therapeutic targets for LGGs remains elusive. To uncover the molecular features of LGGs, functional genomics data have been investigated. Methods: Using public transcriptomics data of LGGs (The Cancer Genome Atlas and GSE107850), differentially expressed genes (DEGs) and differentially co-expressed (DCE) gene pairs between IDH mutation statuses were determined. Gene set enrichment analysis identified the molecular mechanisms of isocitrate dehydrogenase (IDH) mutation in LGGs. Furthermore, the identified DEGs and DCE gene pairs were used for drug repurposing analysis. Results: Two public datasets revealed an overlap of 1527 DEGs. Whereas only seven gene pairs showed significant differential co-expression in both datasets, 1016 genes were simultaneously involved in differential co-expression. Gene set enrichment revealed that biological processes related to neuronal tissue formation were significantly associated with the DEGs. Using drug repurposing analysis, it was found that NVP-TAE684 and bisindolylmaleimide were possible chemical compounds for the LGG treatment. Conclusions: Using transcriptomics data, molecular mechanisms associated with LGG prognosis were identified. This work provides clues for future research on LGG treatment.